natgillin/translations-raw huggingface dataset:
is hydrogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -C(=NH)NR4R5, (CR10R11)pR12, or each R1, R2, R3, R4, R5, R8 and R10 is, independently, hydrogen or C1-C6 alkyl, or R1 and R2 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R2 and R3 together with the atoms to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms, or R1 and R3 together with the atoms to which they are attached can form a carbocyclic ring having from 4 to 6 ring atoms, or R4 and R5 together with the atom to which they are attached can form a heterocyclic ring having from 4 to 6 ring atoms; 
je vodik, po izboru supstituirani aril, po izboru supstituirani aralkil, po izboru supstituirani cikloalkil, po izboru supstituirani cikloalkilalkil, po izboru supstituirani hetcrociklil, po izboru supstituirani heterociklilalkil, po izboru supstituirani heteroaril, po izboru supstituirani heteroarilalkil, -C(=NH)NR4R5, (CR10R11)pR12, [image] svaki R1, R2, R3, R4, R5, R8 and R10 je, neovisno, vodik ili C1-C6 alkil ili R1 i R2 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena ili R1 i R3 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena ili R1 i R3 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena ili R4 i R5 zajedno s atomima za kojih su vezani mogu tvoriti heterociklički prsten koji ima od 4 do 6 atoma prstena;
and R3 together with the atoms to which they are attached form a carbocyclic ring having from 4 to 6 ring atoms. 
i R3 zajedno s atomima za koje su vezani tvore karbociklički prsten koji ima od 4 do 6 atoma prstena.
A compound of claim 4 wherein the compound is: 
Spoj iz patentnog zahtjeva 4, naznačen time, da je spoj:
A pharmaceutical composition comprising a compound of any one of claims 1-22, or a stereoisomer, pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da sadrži spoj iz bilo kojeg od patentnih zahtjeva 1-22 ili stereoizomer, farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
Ra and Rb are independently hydrogen or C1-C3 alkyl; or Ra and Rb combine with the nitrogen atom to which they are attached to form a four to six member heterocyclic group optionally containing an oxygen atom in the ring; wherein the heterocyclic group is further optionally substituted with one or two groups independently selected from C1-C3 alkyl and hydroxyl; 
Ra i Rb su nezavisno vodik ili C1-C3 alkil; ili Ra i R kombinirani sa azotovim atomom za koji su vezani da formiraju heterocikličnu grupu sa četiri do šest članova koja po izboru sadrži kisikov atom u prstenu; gdje je heterociklična grupa dalje po izboru supstituirana sa jednom ili dvije grupe nezavisno izabrane od C1-C3 alkil i hidroksil;
is C1-C3 alkyl or cyclopropyl, wherein the alkyl group is substituted with three fluoro atoms; is hydrogen; is hydrogen; 
je C1-C3 alkil ili ciklopropil, gdje je alkil grupa zamijenjena sa tri atoma fluora; je vodik; je vodik;
Ra and Rb are both C1-C3 alkyl or Ra and Rb combined with the nitrogen atom to which they are attached to form a four to six member heterocyclic group optionally containing an oxygen atom in the ring; wherein the heterocyclic group is further optionally substituted with one or two groups selected from C1-C3 alkyl and hydroxyl; 
Ra i Rb su oba C1-C3 alkil ili Ra i Rb kombinirani sa atomom azota za koji su vezani da formiraju heterocikličnu grupu sa četiri do šest članova koja po izboru sadrži kisikov atom u prstenu: gdje je heterociklična grupa dalje po izboru supstituirana sa jednom ili dvije grupe izabrane od C1-C3alkil i hidroksil;
Ra and Rb are combined with the nitrogen atom to which they are attached to form a heterocyclic group selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl; wherein the heterocyclic group is further optionally substituted with one or two groups selected from C1-C3 alkyl and hydroxyl; or a pharmaceutically acceptable salt or stereoisomer thereof. 
Ra i Rb su kombinirani sa azotovim atomom za koji su vezani da formiraju heterocikličnu grupu izabranu od grupe koja obuhvaća azetidinil, pirolidinil, piperidinil, piperazinil. morfolinil; pri čemu je heterociklična grupa dalje po izboru supstituirana sa jednom ili dvije grupe izabrane od C1-C3 alkil i hidroksil; ili farmaceutski prihvatljiva sol ili stereoizomer tog spoja.
The compound according to Claim 1, wherein R1 is methyl, ethyl, propyl, fluoromethyl, difluormethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, fluoropropyl, difluoropropyl, trifluoropropyl, fluorocyclopropyl, difluorocyclopropyl, or cyclopropyl; 
Spoj prema Patentnom zahtjevu 1, u kome je metil, etil, propil, fluorometil, difluormetil, trifluorometil, fluoroetil, difluoroetil, trifluoroetil. fluoropropil, difluoropropil, trifluoropropil, fluorociklopropil, difluorociklopropil, ili ciklopropil;
Ra and Rb are combined with the nitrogen atom to which they are attached to form a heterocyclic group selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl; wherein the heterocyclic group is further optionally substituted with one or two groups selected from methyl, ethyl, propyl, and hydroxyl; 
Ra i Rb su kombinirani sa azotovim atomom za koji su vezani da formiraju heterocikličnu grupu izabranu od grupe koja obuhvaća azetidinil, pirolidinil, piperidinil, piperazinil, morfolinil; gdje je heterociklična grupa dalje po izboru supstituirana sa jednom ili dvije grupe izabrane od metil, etil, propil, i hidroksil: ili farmaceutski prihvatljiva sol ili stereoizomer tog spoja.
or a pharmaceutically acceptable salt or stereoisomer thereof. 
ili farmaceutski prihvatljiva sol ili stereoizomer tog spoja.
A compound according to Claims 1-10 for use in therapy. 
Spoj prema Patentnim zahtjevima 1-10 za primjenu u terapiji.
A compound according to Claim 12, wherein the therapy is treating autoimmune disorders, inflammatory diseases, cardiovascular diseases (including diabetes, diabetic nephropathy, and other complications of diabetes), cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurodegenerative diseases. 
Spoj prema Patentnom zahtjevu 12, gdje je terapija liječenje autoimunih poremećaja, inflamatornih bolesti, kardiovaskularnih bolesti (uključujući dijabetes, dijabetičnu nefropatiju, i druge komplikacije dijabetesa), kardio-renalnih bolesti, uključujući bolest bubrega, fibrozna oboljenja, respiratorna oboljenja (uključujući COPD (kroničnu opstruktivnu bolest pluća), idiopatsku plućnu fibrozu (IPF), i akutno oštećenje pluća), akutnih i kroničnih bolesti jetre, i neurodegenerativnih bolesti.
L1, L2 are independently a single bond, or unbranched or branched alkyl having 1, 2, 3, 4 or 5 C atoms, which may be unsubstituted, or mono- or disubstituted with Hal, OH, NH2, NH(LA), N(LA)2, and wherein one or two CH2 groups may be replaced by an O atom or by a -CO-, -NH-, -N(LA)-, -CONH-, -N(LA)COO- or -NHCO-group; 
, L2 su neovisno jednostruka veza, ili nerazgranati ili razgranati alkil koji ima 1, 2, 3, 4 ili 5 C atoma, koji mogu biti nesupstituirani, ili mono- ili disupstituirani sa Hal, OH, NH2, NH(LA), N(LA)2, te pri čemu jedna ili dvije skupine CH2 mogu biti zamijenjene sa O atomom ili sa skupinom -CO-, -NH-, -N(LA)-, -CONH-, -N(LA)COO- ili -NHCO-;
is phenyl, which is unsubstituted, or independently mono-, di- or trisubstituted by Hal, C(Hal)3, CH3, CH3O, C(Hal)3O, Ar is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 8, 9, or 10 skeleton atoms, which may be unsubstituted or, indenpendently of one another, mono-, di- or trisubstituted by Hal, A, OA, OH, NH2, or NHA; 
je fenil, koji je nesupstituiran, ili neovisno mono-, di- ili trisupstituiran sa Hal, C(Hal)3, CH3, CH3O, C(Hal)3O, Ar je mono- ili biciklički aromatski homocikal ili heterocikal koji ima 0, 1, 2, 3 ili 4 N, O i/ili S atoma i 5, 6, 8, 9, ili 10 skeletnih atoma, koji mogu biti nesupstituirani ili, međusobno neovisno, mono-, di- ili trisupstituirani sa Hal, A, OA, OH, NH2, ili NHA;
The compound according to Claim 1, wherein the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je spoj odabran iz skupine koju čine:
Set (kit) consisting of separate packs of an effective amount of a compound according to any of Claims 1 to 3 and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient. 
Komplet (kit) naznačen time da sadrži odvojena pakiranja, djelotvorne količine spoja u skladu s bilo kojim od zahtjeva 1 do 3 i/ili njegovi stereoizomeri ili tautomeri, ili farmaceutski prihvatljive soli svakog od navedenih, uključujući njihove smjese u svim omjerima, te učinkovitu količinu dodatnog aktivnog sastojka lijeka.
Polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl)-1 H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 1 for use in the treatment of a disease whose course involves an increased activity of IkB kinase. 
Polimorf 1 od [(S)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida 2-(2-metilamino-pirimidin-4-il)-1 H-indol-5-karboksilne kiseline prema zahtjevu 1 naznačen time da je za uporabu za liječenje bolesti čije tijek uključuje povećanu aktivnost IkB kinaze
Polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl)-1 H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 1 for use in the treatment of inflammatory, immunologically or metabolism-mediated acute and chronic arthritis, arthropathies, rheumatoid arthritis, degenerative joint diseases, spondyloses, diabetes Type II, inflammatory bowel disease, loss of cartilage following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, diseases of the connective tissue, myalgias and disturbances of bone metabolism. 
Polimorf 1 od [(S)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida 2-(2-metilamino-pirimidin-4-il)-1 H-indol-5-karboksilne kiseline prema zahtjevu 1 naznačen time da je za uporabu za liječenje upalnog, imunološkog ili metabolizmom uzrokovanog akutnog i kroničnog artritisa, artropatija, reumatskog artritisa, degenerativnih bolesti zglobova, spondiloza, dijabetesa tipa II, upalne bolesti crijeva, gubitka hrskavice nakon traume zgloba ili dulje imobilizacije zgloba nakon ozljede meniskusa ili ozljede patele ili ruptura ligamenta, bolesti vezivnog tkiva, mialgije i poremećaja metabolizma kosti.
Polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl)-1 H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 1 for use in the treatment of pain including acute pains and chronic pains. 
Polimorf 1 od [(S)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida 2-(2-metilamino-pirimidin-4-il)-1 H-indol-5-karboksilne kiseline prema zahtjevu 1 naznačen time da je za uporabu za liječenje boli, uključujući akutne bolove i kronične bolove.
Polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl)-1 H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 1 for use in the treatment of chronic pain according to claim 7 wherein the chronic pain is selected from chronic musculoskeletal diseases, pains associated with menstrual bleeding, pains associated with osteoarthritis or rheumatoid arthritis, pains associated with intestinal inflammation, pains associated with cardiac muscle inflammation, pains associated with multiple sclerosis, pains associated with neuritis, pains associated with carcinomas and sarcomas, pains associated with AIDS, pains associated with chemotherapy, amputation pain, trigeminus neuralgia, headaches, and neuropathic pains. 
Polimorf 1 od [(S)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida 2-(2-metilamino-pirimidin-4-il)-1 H-indol-5-karboksilne kiseline prema zahtjevu 1 naznačen time da je za uporabu za liječenje kroničnog bola prema zahtjevu 7 pri čemu je kronična bol odabrana od kroničnih koštano-mišićnih bolesti, bolova kod menstrualnog krvarenja, bolova kod osteoartritisa ili reumatoidnog artritisa, bolova kod upale crijeva, bolova kod upale srčanog mišića, bolova kod multiple skleroze, bolova kod neuritisa, bolova kod karcinoma i sarkoma, bolova povezanih s AIDS-om, bolova kod kemoterapije, bolova kod amputacije, trigeminusne neuralgije, glavobolje, te od neuropatskih bolova.
A additive for high temperature naphthenic acid corrosion inhibition comprising a chemical mixture of: 
Aditiv za sprečavanje korozije od naftenske kiseline pri visokoj temperaturi koji se sastoji od kemijske mješavine;
corrosion inhibiting amount of polyisobutylene phosphorous sulphur compound A; and 
spoja A poliizobutilenskog fosfatnog sumpora u količini koja sprječava koroziju; i
corrosion inhibiting amount of thiophosphorous sulphur compound C, wherein said polyisobutylene phosphorous sulphur compound A is obtained by reacting an olefin with phosphorous pentasulphide in presence of catalytic amount of sulphur, forming a reaction mixture, wherein molar ratio of said olefin to said phosphorous pentasulphide is between 1:0.05 to 1:2, said olefin is high reactive polyisobutylene (HRPIB), said sulphur is sulphur powder, and wherein said sulphur powder is present in catalytic quantity of 0.5% to 5% of said olefin by weight; wherein said thiophosphorous sulphur compound C is of the formula 2, is obtained by reacting a thiophosphorous sulphur compound B with ethylene oxide, and wherein the formula 2 comprises resulting compound C obtained after reaction of said compound B with said ethylene oxide, wherein said thiophosphorous sulphur compound C includes mono-ester, di-ester, mixture thereof; wherein X is independently either sulphur or oxygen and at least one X is sulphur, and 
spoja C tiofosfatnog sumpora u količini koja sprječava koroziju, naznačen time da je spoj A poliizobutilenski fosfatni sumpor dobiven reakcijom olefina s fosforovim pentasulfidom u prisutnosti katalitičke količine sumpora, stvarajući reakcijsku mješavinu, gdje je količinski omjer navedenog olefina prema navedenom fosforovom pentasulfidu između 1:0.05 do 1:2, navedem olefin je visoko reaktivan poliizobutilen (HRPIB), navedeni sumpor je sumporov prah, i gdje je navedeni sumporov prah prisutan u katalitičkoj količini od 0,5 % do 5% navedenog olefina prema težini; gdje je navedeni spoj C tiofosfatnog sumpora iz formule 2, dobiven reakcijom spoja B tiofosfatnog sumpora s etilen oksidom, i gdje se formula 2 sastoji od spoja C dobivenog reakcijom navedenog spoja B s etilen oksidom, gdje navedeni spoj C tiofosfatnog sumpora obuhvaća mono-ester, di-ester i njihovu mješavinu;
The additive as claimed in claim 1, wherein said polyisobutylene phosphorus sulphur compound A is obtained by reacting said HRPIB with said phosphorous pentasulphide in the presence of said sulphur powder forming the reaction mixture, 
Aditiv prema patentnom zahtjevu 1, naznačen time da je navedeni spoj A poliizobutilenski fosfatni sumpor dobiven reakcijom navedenog HRPIB-a s navedenim fosforovim pentasulfidom u prisutnosti navedenog sumporova praha stvarajući reakcijsku mješavinu,
by stirring and heating said reaction mixture of said HRPIB said phosphorous pentasulphide and said sulphur powder to a temperature of 160°C under nitrogen gas purging which led to remove hydrogen sulphide (H2S) gas generated during the reaction, 
miješanjem i grijanjem navedene reakcijske mješavine navedenog HRPIB-a navedenog fosforovog pentasulfida i navedenog sumporova praha do temperature od 160°C pročišćavanjem dušikovim plinom što je dovelo do odstranjivanja plina sumporovodika (H2S) generiranog tijekom reakcije,
A process for naphthenic acid corrosion inhibition of metallic surfaces of any of hydrocarbon processing units, with said processing units comprising distillation columns, strippers, trays, and pump around piping, using an additive comprising a mixture of said compound A and said compound C of claim 1, comprising the steps of: 
Postupak za sprečavanje korozije metalnih površina naftenskom kiselinom u postrojenjima za preradu ugljikovodika, naznačen time da se postrojenja za preradu sastoje od destilatora, odstranjivača, korita, pumpi oko cjevovoda, a upotrebljava se aditiv koji se sastoji od mješavine navedenog spoja A i navedenog spoja C iz patentnog zahtjeva 1, koji se sastoji od sljedećih koraka:
condensing a portion of the hydrocarbon vapours, passing through said hydrocarbon processing unit, to produce a condensed distillate; 
kondenziranje dijela ugljikovodičnih para, prolaskom kroz navedeno postrojenje za preradu ugljikovodika, kako bi se proizveo kondenzirani destilat
adding to said distillate, before said condensed distillate is returned to said hydrocarbon processing unit or collected as a product, from 1 ppm to 5000 ppm of said additive, wherein ratio by weight of said compound A to said compound C is from 1:1 to 4:1; 
dodavanje navedenom destilatu, prije nego stoje kondenzirani destilat vraćen u navedeno postrojenje za preradu ugljikovodika ih je pokupljen kao produkt, od 1 ppm do 5000 ppm navedenog aditiva gdje je težinski omjer navedenog spoja A prema spoju C od 1:1 do 4:1;
allowing said condensed distillate containing said additive, to contact said metallic surfaces of said hydrocarbon processing unit, to form a protective film on said surfaces whereby each surface is inhibited against corrosion; and 
dopuštajući navedenom kondenziranom destilatu koji sadrži navedeni aditiv, doticanje navedene metalne površine navedenog postrojenja za preradu ugljikovodika, da načini zaštitni sloj na navedenim površinama čime je svaka površina zaštićena od korozije; i
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula I or a pharmaceutically acceptable salt thereof, wherein: 
Donor nitroksila za primjenu u metodi liječenja plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule I [image] ili njegova farmaceutski prihvatljiva sol, gdje:
The nitroxyl donor of claim 1 for use in a method as defined in claim 1, wherein the effective amount is less than about 1 g/kg/d and/or wherein the mammal is human. 
Donor nitroksila prema patentnom zahtjevu 1 za primjenu u metodi kao što je definirano u patentnom zahtjevu 1, gdje je efikasna količina manja od oko 1 g/kg/d i/ili gdje je sisavac čovjek.
The nitroxyl donor of claim 1 for use in a method as defined in any one of claims 1 to 3, wherein the pulmonary hypertension is pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, or pulmonary hypertension owing to left heart disease, wherein the left heart disease is optionally left heart failure, and wherein the left heart failure is optionally (i) systolic heart failure, (ii) diastolic heart failure, or (iii) chronic or acutely decompensated. 
Donor nitroksila prema patentnom zahtjevu 1 za primjenu u metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 3, gdje plućna hipertenzija je plućna arterijska hipertenzija, kronična tromboembolijska plućna hipertenzija, ili plućna hipertenzija uslijed bolesti lijevog srca, gdje bolest lijevog srca je po izboru lijeva srčana insuficijencija, i gdje je lijeva srčana insuficijencija po izboru (i) sistolna srčana insuficijencija, (ii) dijastolna srčana insuficijencija, ili (iii) kronično ili akutno dekompenzirana.
The nitroxyl donor of claim 1 for use in a method as defined in any one of claims 1 to 4, wherein the nitroxyl donor is a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: is H; is H; 
Donor nitroksila prema patentnom zahtjevu 1 za primjenu u metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 4, gdje je donor nitroksila spoj formule (I): [image] ili njegova farmaceutski prihvatljiva sol, gdje: je H; je H;
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: is H; 
Donor nitroksila za primjenu u metodi za liječenje plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule (I): [image] ili njegova farmaceutski prihvatljiva sol, gdje: je H;
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein: is H; 
Donor nitroksila za primjenu u metodi za liječenje plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule (III) [image] ili njegova farmaceutski prihvatljiva sol, gdje: je H;
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (III): or a pharmaceutically acceptable salt thereof, wherein: 
Donor nitroksila za primjenu u metodi liječenja plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule (III): [image] ili njegova farmaceutski prihvatljiva sol, gdje:
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is: 
Donor nitroksila za primjenu u metodi liječenja plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila: [image] [image]
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein: 
Donor nitroksila za primjenu u metodi liječenja plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule (II): [image] ili njegova farmaceutski prihvatljiva sol, gdje:
m and n are independently an integer from 0 to 1; 
m i n su nezavisno cijeli broj od 0 do 1;
A is a cycloalkyl, heterocycloalkyl, aromatic or heteroaromatic ring containing ring moieties Q1, Q2, Q3 and Q4, which are taken together with the carbons at positions a and a' to form ring A; 
A je cikloalkil, heterocikloalkil, aromatični ili heteroaromatični prsten koji sadrži dijelove prstena Q1, Q2, Q3 i Q4, koji su uzeti zajedno sa ugljicima na pozicijama a i a' da formiraju prsten A;